TABLE 2.
Stability evaluation.
| Sample | Time | Particle size (nm) | PDI | EE (%) |
|---|---|---|---|---|
| rifapentine/PLGA-PEG NPs | Initial | 47.2 ± 7 | 0.19 ± 0.07 | 81.0 ± 6.2 |
| 1 month | 48.1 ± 8 | 0.19 ± 0.06 | 82.4 ± 7.3 | |
| 3 months | 49.4 ± 11 | 0.20 ± 0.07 | 79.1 ± 7.6 | |
| Rifapentine/TC-PLGA-PEG NPs | Initial | 48.8 ± 5.8 | 0.21 ± 0.04 | 83.3 ± 5.5 |
| 1 month | 50.0 ± 8.5 | 0.20 ± 0.06 | 81.7 ± 7.4 | |
| 3 months | 49.5 ± 8.2 | 0.21 ± 0.05 | 80.1 ± 8.3 |
Abbreviations: TC, tetracycline; PLGA, poly-d,l-lactide-co-glycolide; PEG, poly ethylene glycol; NPs, nanoparticles; PDI, polydispersity index; EE, encapsulation efficiency.